Global and regional updates on COVID-19 vaccines–associated myocarditis

Global / Multicontinental COVID-19 vaccine myocarditis signal: updated interpretation CIDRAP summarises current evidence that the early myocarditis signal with mRNA COVID-19 vaccines in young males was real but now appears rare and substantially reduced with updated formulations and spacing. US VSD data suggest rates around 2–5 cases per million doses in 12–39 year olds, with no excess in all cause or cardiac mortality in the 28 days after vaccination. In a press release, Pfizer and Valneva announce that the efficacy of their Lyme Disease vaccine was 73.2% from 28 days post-dose 4 (season 2) in reducing the rate of confirmed Lyme disease cases compared to the placebo. (ViVa13 will cover more details). North America United States – longitudinal myocarditis outcomes after mRNA vaccines Recent follow-up of patients with post mRNA vaccine myocarditis in the US and allied cohorts confirms mostly mild disease with good medium-term recovery, though a subset has persistent symptoms or MRI abnormalities, supporting continued...